Enliven Therapeutics, Inc. Insider Trading

ELVN

Last 12 months

Insiders sold $25.2M and bought nothing on the open market.

96% of the selling was scheduled in advance under 10b5-1 plans. Director J. Scott Garland sold 607K on Oct 1, 100% of their stake, outside a plan. The last open-market buy by an executive or director was in Feb 2022.

Net open-market

−$25.2M

0 buys · 33 sales

Under a 10b5-1 plan

96%

of the value sold

Insiders who bought / sold

0 / 9

executives and directors

Last open-market buy

Feb 2022

Feb 23, 2022

Get an email when ELVN's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Oct 19	Benjamin Hohl Chief Financial Officer	Sold10b5-1 plan	6,018	$38.48	232K	14%	Form 4
Oct 19	Helen Louise Collins Chief Medical Officer	Sold10b5-1 plan	5,000	$38.47	192K	17%	Form 4
Oct 1	J. Scott Garland Director	SoldNo plan	13,000	$46.67	607K	100%	Form 4
Sep 17	Benjamin Hohl Chief Financial Officer	Sold10b5-1 plan 3 parts	6,018	$50.35 average	303K	14%	Form 4
Sep 17	Helen Louise Collins Chief Medical Officer	Sold10b5-1 plan 3 parts	5,000	$50.35 average	252K	17%	Form 4
Aug 17	Benjamin Hohl Chief Financial Officer	Sold10b5-1 plan 2 parts	6,018	$58.58 average	353K	13%	Form 4
Aug 17	Helen Louise Collins Chief Medical Officer	Sold10b5-1 plan 2 parts	5,000	$58.59 average	293K	17%	Form 4
Aug 4	Mika K Derynck Director	Sold10b5-1 plan	158,795	$60.21	$9.56M	100%	Form 4
Jul 17	Benjamin Hohl Chief Financial Officer	Sold10b5-1 plan 5 parts	6,018	$52.64 average	317K	12%	Form 4
Jul 17	Helen Louise Collins Chief Medical Officer	Sold10b5-1 plan 5 parts	5,000	$52.67 average	263K	17%	Form 4
Jul 6	Lori Anne Kunkel Director	Sold10b5-1 plan 2 parts	10,000	$50.49 average	505K	19%	Form 4
Jun 22	Orbimed Advisors LLC Large holder	SoldNo plan 4 parts	860,123	$45.36 average	$39M	12%	Form 4
Jun 17	Benjamin Hohl Chief Financial Officer	Sold10b5-1 plan 3 parts	6,018	$43.80 average	264K	11%	Form 4
Jun 17	Helen Louise Collins Chief Medical Officer	Sold10b5-1 plan 3 parts	5,000	$43.80 average	219K	17%	Form 4
Jun 15	Orbimed Advisors LLC Large holder	SoldNo plan 2 parts	281,408	$45.02 average	$12.7M	3.7%	Form 4
Jun 5	Lori Anne Kunkel Director	Sold10b5-1 plan 3 parts	10,000	$34.54 average	345K	16%	Form 4
May 18	Helen Louise Collins Chief Medical Officer	Sold10b5-1 plan 3 parts	5,000	$39.79 average	199K	17%	Form 4
Apr 17	Helen Louise Collins Chief Medical Officer	Sold10b5-1 plan 3 parts	5,000	$47.67 average	238K	17%	Form 4
Mar 25	Helen Louise Collins Chief Medical Officer	Sold10b5-1 plan	40,000	$35.10	$1.4M	62%	Form 4
Mar 17	Helen Louise Collins Chief Medical Officer	Sold10b5-1 plan	5,000	$27.76	139K	17%	Form 4
Mar 9 – 10	Helen Louise Collins Chief Medical Officer	Sold10b5-1 plan 2 parts	40,000	$30.06 average	$1.2M	62%	Form 4
Mar 6	Benjamin Hohl Chief Financial Officer	SoldNo plan	10,000	$29.58	296K	16%	Form 4
Feb 17	Helen Louise Collins Chief Medical Officer	Sold10b5-1 plan	45,000	$26.17	$1.18M	64%	Form 4
Feb 17	Richard A. Heyman Director	Sold10b5-1 plan	1,230	$26.18	32K	0.8%	Form 4
Feb 6	Joseph P Lyssikatos Chief Scientific Officer	Sold10b5-1 plan	5,000	$29.04	145K	0.7%	Form 4
Jan 20	Joseph P Lyssikatos Chief Scientific Officer	Sold10b5-1 plan 2 parts	20,000	$26.75 average	535K	2.6%	Form 4
Jan 20	Richard A. Heyman Director	Sold10b5-1 plan 2 parts	1,230	$26.75 average	33K	0.8%	Form 4
Jan 9	Anish Patel Chief Operating Officer	Sold10b5-1 plan 2 parts	48,300	$27.98 average	$1.35M	18%	Form 4
Jan 8 – 9	Joseph P Lyssikatos Chief Scientific Officer	Sold10b5-1 plan 4 parts	132,500	$26.23 average	$3.48M	15%	Form 4
Jan 8 – 9	Richard A. Heyman Director	Sold10b5-1 plan 3 parts	13,920	$25.02 average	348K	8.6%	Form 4
Dec 19, 2025	Joseph P Lyssikatos Chief Scientific Officer	Sold10b5-1 plan	5,000	$16.84	84K	0.6%	Form 4
Dec 8, 2025	Anish Patel Chief Operating Officer	Sold10b5-1 plan 2 parts	6,663	$21.02 average	140K	2.5%	Form 4
Nov 19, 2025	Joseph P Lyssikatos Chief Scientific Officer	Sold10b5-1 plan 2 parts	12,500	$22.33 average	279K	1.4%	Form 4
Nov 17, 2025	Samuel Kintz President and CEO	Sold10b5-1 plan	12,500	$21.82	273K	1.4%	Form 4
Nov 7, 2025	Anish Patel Chief Operating Officer	Sold10b5-1 plan 2 parts	6,667	$17.40 average	116K	2.4%	Form 4
Oct 20, 2025	Joseph P Lyssikatos Chief Scientific Officer	Sold10b5-1 plan	12,500	$22.08	276K	1.3%	Form 4
Oct 17, 2025	Samuel Kintz President and CEO	Sold10b5-1 plan	12,500	$21.33	267K	1.4%	Form 4
Oct 7, 2025	Anish Patel Chief Operating Officer	Sold10b5-1 plan	6,667	$20.10	134K	2.4%	Form 4
Sep 29, 2025	Benjamin Hohl Chief Financial Officer	Sold10b5-1 plan	3,250	$20.40	66K	12%	Form 4
Sep 26, 2025	Samuel Kintz President and CEO	Sold10b5-1 plan	3,700	$20.06	74K	0.4%	Form 4

Oct 1910b5-1 plan
Benjamin Hohl
Chief Financial Officer · sold 6,018 at $38.48
232K
14% of stake
Oct 1910b5-1 plan
Helen Louise Collins
Chief Medical Officer · sold 5,000 at $38.47
192K
17% of stake
Oct 1No plan
J. Scott Garland
Director · sold 13,000 at $46.67
607K
100% of stake
Sep 1710b5-1 plan
Benjamin Hohl
Chief Financial Officer · sold 6,018 at avg $50.35
303K
14% of stake
Sep 1710b5-1 plan
Helen Louise Collins
Chief Medical Officer · sold 5,000 at avg $50.35
252K
17% of stake
Aug 1710b5-1 plan
Benjamin Hohl
Chief Financial Officer · sold 6,018 at avg $58.58
353K
13% of stake
Aug 1710b5-1 plan
Helen Louise Collins
Chief Medical Officer · sold 5,000 at avg $58.59
293K
17% of stake
Aug 410b5-1 plan
Mika K Derynck
Director · sold 158,795 at $60.21
$9.56M
100% of stake
Jul 1710b5-1 plan
Benjamin Hohl
Chief Financial Officer · sold 6,018 at avg $52.64
317K
12% of stake
Jul 1710b5-1 plan
Helen Louise Collins
Chief Medical Officer · sold 5,000 at avg $52.67
263K
17% of stake
Jul 610b5-1 plan
Lori Anne Kunkel
Director · sold 10,000 at avg $50.49
505K
19% of stake
Jun 22No plan
Orbimed Advisors LLC
Large holder · sold 860,123 at avg $45.36
$39M
12% of stake
Jun 1710b5-1 plan
Benjamin Hohl
Chief Financial Officer · sold 6,018 at avg $43.80
264K
11% of stake
Jun 1710b5-1 plan
Helen Louise Collins
Chief Medical Officer · sold 5,000 at avg $43.80
219K
17% of stake
Jun 15No plan
Orbimed Advisors LLC
Large holder · sold 281,408 at avg $45.02
$12.7M
3.7% of stake
Jun 510b5-1 plan
Lori Anne Kunkel
Director · sold 10,000 at avg $34.54
345K
16% of stake
May 1810b5-1 plan
Helen Louise Collins
Chief Medical Officer · sold 5,000 at avg $39.79
199K
17% of stake
Apr 1710b5-1 plan
Helen Louise Collins
Chief Medical Officer · sold 5,000 at avg $47.67
238K
17% of stake
Mar 2510b5-1 plan
Helen Louise Collins
Chief Medical Officer · sold 40,000 at $35.10
$1.4M
62% of stake
Mar 1710b5-1 plan
Helen Louise Collins
Chief Medical Officer · sold 5,000 at $27.76
139K
17% of stake
Mar 9 – 1010b5-1 plan
Helen Louise Collins
Chief Medical Officer · sold 40,000 at avg $30.06
$1.2M
62% of stake
Mar 6No plan
Benjamin Hohl
Chief Financial Officer · sold 10,000 at $29.58
296K
16% of stake
Feb 1710b5-1 plan
Helen Louise Collins
Chief Medical Officer · sold 45,000 at $26.17
$1.18M
64% of stake
Feb 1710b5-1 plan
Richard A. Heyman
Director · sold 1,230 at $26.18
32K
0.8% of stake
Feb 610b5-1 plan
Joseph P Lyssikatos
Chief Scientific Officer · sold 5,000 at $29.04
145K
0.7% of stake
Jan 2010b5-1 plan
Joseph P Lyssikatos
Chief Scientific Officer · sold 20,000 at avg $26.75
535K
2.6% of stake
Jan 2010b5-1 plan
Richard A. Heyman
Director · sold 1,230 at avg $26.75
33K
0.8% of stake
Jan 910b5-1 plan
Anish Patel
Chief Operating Officer · sold 48,300 at avg $27.98
$1.35M
18% of stake
Jan 8 – 910b5-1 plan
Joseph P Lyssikatos
Chief Scientific Officer · sold 132,500 at avg $26.23
$3.48M
15% of stake
Jan 8 – 910b5-1 plan
Richard A. Heyman
Director · sold 13,920 at avg $25.02
348K
8.6% of stake
Dec 19, 202510b5-1 plan
Joseph P Lyssikatos
Chief Scientific Officer · sold 5,000 at $16.84
84K
0.6% of stake
Dec 8, 202510b5-1 plan
Anish Patel
Chief Operating Officer · sold 6,663 at avg $21.02
140K
2.5% of stake
Nov 19, 202510b5-1 plan
Joseph P Lyssikatos
Chief Scientific Officer · sold 12,500 at avg $22.33
279K
1.4% of stake
Nov 17, 202510b5-1 plan
Samuel Kintz
President and CEO · sold 12,500 at $21.82
273K
1.4% of stake
Nov 7, 202510b5-1 plan
Anish Patel
Chief Operating Officer · sold 6,667 at avg $17.40
116K
2.4% of stake
Oct 20, 202510b5-1 plan
Joseph P Lyssikatos
Chief Scientific Officer · sold 12,500 at $22.08
276K
1.3% of stake
Oct 17, 202510b5-1 plan
Samuel Kintz
President and CEO · sold 12,500 at $21.33
267K
1.4% of stake
Oct 7, 202510b5-1 plan
Anish Patel
Chief Operating Officer · sold 6,667 at $20.10
134K
2.4% of stake
Sep 29, 202510b5-1 plan
Benjamin Hohl
Chief Financial Officer · sold 3,250 at $20.40
66K
12% of stake
Sep 26, 202510b5-1 plan
Samuel Kintz
President and CEO · sold 3,700 at $20.06
74K
0.4% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch ELVN, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with ELVN

CompareIntrinsic value

AKBAAkebia Therapeutics Inc.

$0.69-4.31%49

ACADAcadia Pharmaceuticals Inc.

$21.49+4.47%74

NAMSNewAmsterdam Pharma Co. N.V.

$20.93+5.18%10

EOLSEvolus Inc.

$7.47+1.36%30

MCRBSeres Therapeutics, Inc.

$2.13+8.42%0

ZVRAZevra Therapeutics, Inc.

$11.17+8.87%83

ARQTArcutis Biotherapeutics Inc.

$34.05+6.41%65

URGNUrogen Pharma Ltd.

$28.71-16.54%30

Held by ETFs

ELVN is in 45 US ETFs. The largest of them, with ELVN's weight in each:

Spot a number that looks wrong? Check it in ELVN's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing ELVN

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.